التفاصيل البيبلوغرافية
| العنوان: |
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. |
| المؤلفون: |
Lebow, Emily S., Shaverdian, Narek, Eichholz, Jordan E., Kratochvil, Leah B., McCune, Megan, Murciano-Goroff, Yonina R., Jee, Justin, Eng, Juliana, Chaft, Jamie E., Kris, Mark G., Kalashnikova, Ekaterina, Feeney, Jordan, Scalise, Carly Bess, Sudhaman, Sumedha, Palsuledesai, Charuta C., Malhotra, Meenakshi, Krainock, Michael, Sethi, Himanshu, Aleshin, Alexey, Liu, Minetta C. |
| المصدر: |
Frontiers in Oncology; 2023, p01-07, 7p |
| مصطلحات موضوعية: |
NON-small-cell lung carcinoma, CIRCULATING tumor DNA, CANCER patients, SINGLE nucleotide polymorphisms, CANCER relapse, DISEASE progression |
| مستخلص: |
Background: Sensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally advanced non-small cell lung cancer (NSCLC) who are treated with definitive radiation therapy (RT). This prospective, multistate single-center, cohort study investigated the association of circulating tumor DNA (ctDNA) status with recurrence in patients with unresectable stage I-III NSCLC who underwent definitive RT. Methods: A total of 70 serial plasma samples from 17 NSCLC patients were collected before, during, and after treatment. A personalized, tumor-informed ctDNA assay was used to track a set of up to 16 somatic, single nucleotide variants in the associated patient's plasma samples. Results: Pre-treatment ctDNA detection rate was 82% (14/17) and varied based on histology and stage. ctDNA was detected in 35% (6/17) of patients at the first post-RT timepoint (median of 1.66 months following the completion of RT), all of whom subsequently developed clinical progression. At this first post-RT time point, patients with ctDNA-positivity had significantly worse progression-free survival (PFS) [hazard ratio (HR): 24.2, p=0.004], and ctDNA-positivity was the only significant prognostic factor associated with PFS (HR: 13.4, p=0.02) in a multivariate analysis. All patients who developed clinical recurrence had detectable ctDNA with an average lead time over radiographic progression of 5.4 months, and post-RT ctDNA positivity was significantly associated with poor PFS (p<0.0001). Conclusion: Personalized, longitudinal ctDNA monitoring can detect recurrence early in patients with unresectable NSCLC patients undergoing curative radiation and potentially risk-stratify patients who might benefit most from treatment intensification. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder